Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2022 · 10-K
Revenue$9.12M$9.12M+9.7% vs Q4 2021 Net Income-$2.44M-$2.44MN/M vs Q4 2021 EPS Diluted-$0.17-$0.17N/M vs Q4 2021 Operating Income-$2,277,804N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$3,791,559+94.4% Margins · derivedOperating margin-25.0%+27.4 pt vs Q4 2021
Net margin-26.8%+19.5 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 13, 2023 · 72 d after period end